Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine.

< BACK TO ARCHIVE


2022 Jul 27


BMC Infect Dis


http://www.ncbi.nlm.nih.gov/pubmed/35896987?dopt=Abstract


22


1

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine.

Authors

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine.
Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I
BMC Infect Dis. 2022 Jul 27; 22(1):650.
PMID: 35896987.

Abstract

Direct-acting antivirals (DAAs) are highly effective in achieving sustained virologic response among those with chronic hepatitis C virus (HCV) infection. Quality of life (QOL) benefits for an HCV-infected population with high numbers of people who inject drugs and people living with HIV (PLHIV) in Eastern Europe have not been explored. We estimated such benefits for Ukraine.
Read This Paper